MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
2.080
-0.070
-3.26%
Opening 14:08 01/22 EST
OPEN
2.160
PREV CLOSE
2.150
HIGH
2.160
LOW
2.070
VOLUME
3.62M
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
1.580
MARKET CAP
409.83M
P/E (TTM)
-3.1587
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESPR last week (0113-0117)?
Weekly Report · 2d ago
Bank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)
TipRanks · 6d ago
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
NASDAQ · 01/14 14:07
Weekly Report: what happened at ESPR last week (0106-0110)?
Weekly Report · 01/13 11:56
Esperion’s Strategic International Expansion and Revenue Growth Justify Buy Rating
TipRanks · 01/10 11:26
Weekly Report: what happened at ESPR last week (1230-0103)?
Weekly Report · 01/06 12:06
Esperion (ESPR) Gets a Sell from Bank of America Securities
TipRanks · 01/06 11:37
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Barchart · 01/02 07:00
More
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.